Start with its own history
At 31.29×, ESALF is 11.0% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
OTC · ESALFDrug Manufacturers - Specialty & GenericUpdated Nov 5, 2026
Eisai Co., Ltd. P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
31.29×
11.0% belowthe 10-year annual average
Share price29.97
÷Earnings per share0.9577
Price and EPS in quote currency. Calculation details
Investors are paying 31.29 for every 1 of reported earnings per share.
P/E over time
2017 – 2026
Annual P/ESelected-period average 35.16×
3-year average34.01×3 positive annual observations
5-year average34.95×5 positive annual observations
10-year average35.16×10 positive annual observations
Peer median · TTM17.71×8 peers with positive P/E
Historical P/E ratios
Annual period-end data · 15 observations
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2026 | 35.61× | +40.7% |
| Mar 31, 2025 | 25.31× | -38.4% |
| Mar 31, 2024 | 41.11× | +5.9% |
| Mar 31, 2023 | 38.82× | +14.5% |
| Mar 31, 2022 | 33.90× | -32.9% |
| Mar 31, 2021 | 50.49× | +170.5% |
| Mar 31, 2020 | 18.66× | -34.2% |
| Mar 31, 2019 | 28.36× | -24.2% |
View all 15 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2018 | 37.43× | -10.6% |
| Mar 31, 2017 | 41.88× | +18.9% |
| Mar 31, 2016 | 35.22× | -37.5% |
| Mar 31, 2015 | 56.31× | +88.0% |
| Mar 31, 2014 | 29.96× | +25.1% |
| Mar 31, 2013 | 23.94× | +49.4% |
| Mar 31, 2012 | 16.02× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How ESALF compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 ESALF This stockEisai Co., Ltd. | 31.29× |
 4151.TKyowa Kirin Co., Ltd. | 15.93× |
 4528.TOno Pharmaceutical Co., Ltd. | 15.68× |
 4507.TShionogi & Co., Ltd. | 11.26× |
 4503.TAstellas Pharma Inc. | 13.12× |
 4568.TDaiichi Sankyo Company, Limited | 20.10× |
 4519.TChugai Pharmaceutical Co., Ltd. | 23.49× |
 4502.TTakeda Pharmaceutical Company Limited | 28.13× |
 4506.TSumitomo Pharma Co., Ltd. | 19.50× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does ESALF’s P/E tell you?
Compare like with like
The median of the 8 positive peer ratios above is 17.71×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take ESALF into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("ESALF", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 29.97 ÷ EPS 0.9577 = 31.29×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 5, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
ESALF P/E ratio: common questions
The essentials behind the numbers.
Eisai Co., Ltd.'s current P/E is 31.29× based on the quote data last updated Nov 5, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.